Kodiak Sciences says Zenkuda meets primary endpoint in Phase 3 DAYBREAK wet AMD trial

• Kodiak Sciences reported pivotal Phase 3 DAYBREAK trial success in wet age-related macular degeneration for Zenkuda and tabirafusp-ted.
• Both treatments matched aflibercept on vision outcomes at one year, supporting a potential path toward first-line use.
• Zenkuda showed rapid disease control with longer dosing intervals for many patients, strengthening its commercial positioning versus standard anti-VEGF therapy.
• The company plans a multi-indication Zenkuda BLA submission in 4Q2026, anchored by five positive Phase 3 studies.
• Detailed DAYBREAK results will be presented at a company Webex on Sept. 28, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609280630PR_NEWS_USPR_____SF57778) on September 28, 2026, and is solely responsible for the information contained therein.